Fluoxetine modulates hippocampal cell signaling pathways implicated in neuroplasticity in olfactory bulbectomized mice

Behavioural Brain Research

Volumn 237, Issue 1, 2013, Pages 176-184

  Freitas, Andiara E ^a   Machado, Daniele G ^a   Budni, Josiane ^a   Neis, Vivian B ^a   Balen, Grasiela O ^a   Lopes, Mark W ^a   de Souza, Luiz Felipe ^a   Dafre, Alcir L ^a   Leal, Rodrigo B ^a   Rodrigues, Ana Lúcia S ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Antidepressant; BDNF; CREB; ERK1 2; Fluoxetine; Olfactory bulbectomy

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FLUOXETINE; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DEPRESSION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HIPPOCAMPUS; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANALYSIS OF VARIANCE; ANHEDONIA; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BRAIN-DERIVED NEUROTROPHIC FACTOR; CREB-BINDING PROTEIN; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; FEMALE; FLUOXETINE; FOOD PREFERENCES; GENE EXPRESSION REGULATION; GLYCOGEN SYNTHASE KINASE 3; HIPPOCAMPUS; HYPERKINESIS; MAP KINASE SIGNALING SYSTEM; MICE; NEURONAL PLASTICITY; NEURONS; OLFACTION DISORDERS; OLFACTORY BULB; ONCOGENE PROTEIN V-AKT; SIGNAL TRANSDUCTION;

EID: 84867606560     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.09.035     Document Type: Article

References (76)

1. Kessler R.C., Berglund P., Demler O., Jin R., Merikangas K.R., Walters E.E. Lifetime prevalence and age-of-onsetdistributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 2005, 62:593-602.
2. Cipriani A., Brambilla P., Furukawa T., Geddes J., Gregis M., Hotopf M., et al. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database of Systematic Reviews 2005, 4:CD004185.
3. Schmidt H.D., Duman R.S. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behavioural Pharmacology 2007, 18:391-418.
4. Sairanen M., Lucas G., Ernfors P., Castrén M., Castrén E. Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. Journal of Neuroscience 2005, 25:1089-1094.
5. Russo-Neustadt A.A., Chen M.J. Brain-derived neurotrophic factor and antidepressant activity. Current Pharmaceutical Design 2005, 11:1495-1510.
6. Numakawa T., Suzuki S., Kumamaru E., Adachi N., Richards M., Kunugi H. BDNF function and intracellular signaling in neurons. Histology and Histopathology 2010, 25:237-258.
7. Chen M.J., Nguyen T.V., Pike C.J., Russo-Neustadt A.A. Norepinephrine induces BDNF and activates the PI-3K and MAPK cascades in embryonic hippocampal neurons. Cellular Signalling 2007, 19:114-128.
8. Tardito D., Perez J., Tiraboschi E., Musazzi L., Racagni G., Popoli M. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacological Reviews 2006, 58:115-134.
9. Beaulieu J.M., Gainetdinov R.R., Caron M.G. Akt/GSK3 signaling in the action of psychotropic drugs. Annual Review of Pharmacology and Toxicology 2009, 49:327-347.
10. Beaulieu J.M. Not only lithium: regulation of glycogen synthase kinase-3 by antipsychotics and serotonergic drugs. International Journal of Neuropsychopharmacology 2007, 10:3-6.
11. Li X., Zhu W., Roh M.S., Friedman A.B., Rosborough K., Jope R.S. In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 2004, 29:1426-1431.
12. Li X., Rosborough K.M., Friedman A.B., Zhu W., Roth K.A. Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. International Journal of Neuropsychopharmacology 2007, 10:7-19.
13. Cryan J.F., Holmes A. The ascent of mouse: advances in modeling human depression and anxiety. Nature Reviews Drug Discovery 2005, 4:775-790.
14. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron 2002, 34:13-25.
15. Leonard B.E. The olfactory bulbectomized rat as a model of depression. Polish Journal of Pharmacology and Pharmacy 1984, 36:561-569.
16. Kelly J.P., Wrynn A.S., Leonard B.E. The olfactory bulbectomized rat as a model of depression: an update. Pharmacology & Therapeutics 1997, 74:299-316.
17. Song C., Leonard B.E. The olfactory bulbectomised rat as a model of depression. Neuroscience and Biobehavioral Reviews 2005, 29:627-647.
18. Gary D.S., Getchell T.V., Getchell M.L., Mattson M.P. Olfactory bulbectomy protects hippocampal pyramidal neurons against excitotoxic death. Experimental Neurology 2002, 176:266-268.
19. Leonard B.E., Tuite M. Anatomical, physiological, and behavioral aspects of olfactory bulbectomy in the rat. International Review of Neurobiology 1981, 22:251-286.
20. Zueger M., Urani A., Chourbaji S., Zacher C., Roche M., Harkin A., et al. Olfactory bulbectomy in mice induces alterations in exploratory behavior. Neuroscience Letters 2005, 374:142-146.
21. Rodrigues A.L.S., Rocha J.B., Mello C.F., Souza D.O. Effect of perinatal lead exposure on rat behaviour in open-field and two-way avoidance tasks. Pharmacology & Toxicology 1996, 79:150-156.
22. Isingrini E., Camus V., Le Guisquet A.M., Pingaud M., Devers S., Belzung C. Association between repeated unpredictable chronic mild stress (UCMS) procedures with a high fat diet: a model of fluoxetine resistance in mice. PLoS One 2010, 5:e10404.
23. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 2005, 52:90-110.
24. Yalcin I., Aksu F., Belzung C. Effects of desipramine and tramadol in a chronic mild stress model in mice are altered by yohimbine but not by pindolol. European Journal of Pharmacology 2005, 514:165-174.
25. Leal R.B., Cordova F.M., Herd L., Bobrovskaya L., Dunkley P.R. Lead-stimulated p38MAPKdependent Hsp27 phosphorylation. Toxicology and Applied Pharmacology 2002, 178:44-51.
26. Cordova F.M., Rodrigues A.L.S., Giacomelli M.B., Oliveira C.S., Posser T., Dunkley P.R., et al. Lead stimulates ERK1/2 and p38MAPK phosphorylation in the hippocampus of immature rats. Brain Research 2004, 998:65-72.
27. Peterson G.L. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Analytical Biochemistry 1977, 83:346-356.
28. Posser T., de Aguiar C.B., Garcez R.C., Rossi F.M., Oliveira C.S., Trentin A.G., et al. Exposure of C6 glioma cells to Pb(II) increases the phosphorylation of p38 (MAPK) and JNK1/2 but not of ERK1/2. Archives of Toxicology 2007, 81:407-414.
29. Wong M.L., Licinio J. Research and treatment approaches to depression. Nature Reviews Neuroscience 2001, 2:343-351.
30. Stock H.S., Hand G.A., Ford K., Wilson M.A. Changes in defensive behaviors following olfactory bulbectomy in male and female rats. Brain Research 2001, 1-2:242-246.
31. Stock H.S., Ford K., Wilson M.A. Gender and gonadal hormone effects in the olfactory bulbectomy animal model of depression. Pharmacology Biochemistry and Behavior 2000, 67:183-191.
32. American Psychiatry Association Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Association, Washington, DC. 4th ed.
33. Machado D.G., Cunha M.P., Neis V.B., Balen G.O., Colla A.R., Grando J., et al. Rosmarinus officinalis L. hydroalcoholic extract, similar to fluoxetine, reverses depressive-like behavior without altering learning deficit in olfactory bulbectomized mice. Journal of Ethnopharmacology 2012, 143:158-169.
34. Mar A., Spreekmeester E., Rochford J. Fluoxetine-induced increases in open-field habituation in the olfactory bulbectomized rat depend on test aversiveness but not on anxiety. Pharmacology Biochemistry and Behavior 2002, 73:703-712.
35. Roche M., Harkin A., Kelly J.P. Chronic fluoxetine treatment attenuates stressor-induced changes in temperature, heart rate, and neuronal activation in the olfactory bulbectomized rat. Neuropsychopharmacology 2007, 32:1312-1320.
36. Jarosik J., Legutko B., Unsicker K., von Bohlen Und Halbach O. Antidepressant-mediated reversal of abnormal behavior and neurodegeneration in mice following olfactory bulbectomy. Experimental Neurology 2007, 204:20-28.
37. McGrath C., Norman T.R. The effect of venlafaxine treatment on the behavioural and neurochemical changes in the olfactory bulbectomised rat. Psychopharmacology 1998, 136:394-401.
38. Farley S., Dumas S., El Mestikawy S., Giros B. Increased expression of the Vesicular Glutamate Transporter-1 (VGLUT1) in the prefrontal cortex correlates with differential vulnerability to chronic stress in various mouse strains: effects of fluoxetine and MK-801. Neuropharmacology 2012, 62:503-517.
39. Cornelisse L.N., Van der Harst J.E., Lodder J.C., Baarendse P.J., Timmerman A.J., Mansvelder H.D., et al. Reduced 5-HT1A- and GABAB receptor function in dorsal raphe neurons upon chronic fluoxetine treatment of socially stressed rats. Journal of Neurophysiology 2007, 98:196-204.
40. Sigwalt A.R., Budde H., Helmich I., Glaser V., Ghisoni K., Lanza S., et al. Molecular aspects involved in swimming exercise training reducing anhedonia in a rat model of depression. Neuroscience 2011, 192:661-674.
41. Sammut S., Bethus I., Goodall G., Muscat R. Antidepressant reversal of interferon-alpha-induced anhedonia. Physiology and Behavior 2002, 75:765-772.
42. Lalonde R., Strazielle C. The relation between open-field and emergence tests in a hyperactive mouse model. Neuropharmacology 2009, 57:722-724.
43. Einat H., Yuan P., Gould T.D., Li J., Du J., Zhang L., et al. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. Journal of Neuroscience 2003, 23:7311-7316.
44. Vidal R., Pilar-Cuéllar F., dos Anjos S., Linge R., Treceño B., Vargas V.I., et al. New strategies in the development of antidepressants: towards the modulation of neuroplasticity pathways. Current Pharmaceutical Design 2011, 17:521-533.
45. Jope R.S., Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends in Biochemical Sciences 2004, 29:95-102.
46. Peineau S., Bradley C., Taghibiglou C., Doherty A., Bortolotto Z.A., Wang Y.T., et al. The role of GSK-3 in synaptic plasticity. British Journal of Pharmacology 2008, 153:S428-S437.
47. Hur E.M., Zhou F.Q. GSK3 signalling in neural development. Nature Reviews Neuroscience 2010, 11:539-551.
48. Rosa A.O., Kaster M.P., Binfaré R.W., Morales S., Martín-Aparicio E., Navarro-Rico M.L., et al. Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008, 32:1549-1556.
49. Doble B.W., Woodgett J.R. GSK-3: tricks of the trade for a multi-task kinase. Journal of Cell Science 2003, 116:1175-1186.
50. Song G., Ouyang G., Bao S. The activation of Akt/PKB signaling pathway and cell survival. Journal of Cellular and Molecular Medicine 2005, 9:59-71.
51. Nicholson K.M., Anderson N.G. The protein kinase B/Akt signalling pathway in human malignancy. Cellular Signalling 2002, 14:381-395.
52. Shioda N., Yamamoto Y., Han F., Moriguchi S., Yamaguchi Y., Hino M., et al. A novel cognitive enhancer ZSET1446/ST101, promotes hippocampal neurogenesis and ameliorates depressive behavior in olfactory bulbectomized mice. Journal of Pharmacology and Experimental Therapeutics 2010, 333:43-50.
53. Johnson G.L., Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK JNK, and p38 protein kinases. Science 2002, 298:1911-1912.
54. Strnisková M., Barancík M., Ravingerová T. Mitogen-activated protein kinases and their role in regulation of cellular processes. General Physiology and Biophysics 2002, 21:231-255.
55. Stork P.J., Schmitt J.M. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends in Cell Biology 2002, 12:258-266.
56. Sweatt J.D. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. Journal of Neurochemistry 2001, 76:1-10.
57. Thomas G.M., Huganir R.L. MAPK cascade signalling and synaptic plasticity. Nature Reviews Neuroscience 2004, 5:173-183.
58. Fumagalli F., Molteni R., Calabrese F., Frasca A., Racagni G., Riva M.A. Chronic fluoxetine administration inhibits extracellular signal-related kinase 1/2 phosphorylation in rat brain. Journal of Neurochemistry 2005, 93:1551-1560.
59. Todorovic C., Sherrin T., Pitts M., Hippel C., Rayner M., Spiess J. Suppression of the MEK/ERK signaling pathway reverses depression-like behaviors of CRF2-deficient mice. Neuropsychopharmacology 2009, 34:1416-1426.
60. Bravo J.A., Díaz-Veliz G., Mora S., Ulloa J.L., Berthoud V.M., Morales P., et al. Desipramine prevents stress-induced changes in depressive-like behavior and hippocampal markers of neuroprotection. Behavioural Pharmacology 2009, 20:273-285.
61. Galeotti N., Ghelardini C. Regionally selective activation and differential regulation of ERK JNK and p38 MAP kinase signalling pathway by protein kinase C in mood modulation. International Journal of Neuropsychopharmacology 2011, 20:1-13.
62. Lonze B.E., Ginty D.D. Function and regulation of CREB family transcription factors in the nervous system. Neuron 2002, 35:605-623.
63. Shaywitz A.J., Greenberg M.E. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annual Review of Biochemistry 1999, 68:821-861.
64. Han F., Nakano T., Yamamoto Y., Shioda N., Lu Y.M., Fukunaga K. Improvement of depressive behaviors by nefiracetam is associated with activation of CaM kinases in olfactory bulbectomized mice. Brain Research 2009, 1265:205-214.
65. Wang D., Noda Y., Tsunekawa H., Zhou Y., Miyazaki M., Senzaki K., et al. Behavioural and neurochemical features of olfactory bulbectomized rats resembling depression with comorbid anxiety. Behavioural Brain Research 2007, 178:262-273.
66. Romeas T., Morissette M.C., Mnie-Filali O., Piñeyro G., Boye S.M. Simultaneous anhedonia and exaggerated locomotor activation in an animal model of depression. Psychopharmacology 2009, 205:293-303.
67. Gass P., Riva M.A. CREB: neurogenesis and depression. Bioessays 2007, 29:957-961.
68. Kageyama K., Akimoto K., Suda T. Corticotrophin-releasing factor gene transcription is directly activated after deprivation of glucocorticoids in hypothalamic cells. Journal of Neuroendocrinology 2010, 22:971-978.
69. Delivoria-Papadopoulos M., Ashraf Q.M., Mishra O.P. Brain tissue energy dependence of CaM kinase IV cascade activation during hypoxia in the cerebral cortex of newborn piglets. Neuroscience Letters 2011, 491:113-117.
70. Böer U., Alejel T., Beimesche S., Cierny I., Krause D., Knepel W., et al. CRE/CREB-driven up-regulation of gene expression by chronic social stress in CRE-luciferase transgenic mice: reversal by antidepressant treatment. PLoS One 2007, 2:e431.
71. Böer U., Noll C., Cierny I., Krause D., Hiemke C., Knepel W. A common mechanism of action of the selective serotonin reuptake inhibitors citalopram and fluoxetine: reversal of chronic psychosocial stress-induced increase in CRE/CREB-directed gene transcription in transgenic reporter gene mice. European Journal of Pharmacology 2010, 633:33-38.
72. Hellweg R., Zueger M., Fink K., Hörtnagl H., Gass P. Olfactory bulbectomy in mice leads to increased BDNF levels and decreased serotonin turnover in depression-related brain areas. Neurobiology of Disease 2007, 25:1-7.
73. Luo K.R., Hong C.J., Liou Y.J., Hou S.J., Huang Y.H., Tsai S.J. Differential regulation of neurotrophin S100B and BDNF in two rat models of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2010, 34:1433-1439.
74. Van Hoomissen J.D., Chambliss H.O., Holmes P.V., Dishman R.K. Effects of chronic exercise and imipramine on mRNA for BDNF after olfactory bulbectomy in rat. Brain Research 2003, 974:228-235.
75. Hendriksen H., Meulendijks D., Douma T.N., Bink D.I., Breuer M.E., Westphal K.G., et al. Environmental enrichment has antidepressant-like action without improving learning and memory deficits in olfactory bulbectomized rats. Neuropharmacology 2012, 62:270-277.
76. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Archives of General Psychiatry 1997, 54:597-606.